Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Yate-Ching Yuan"'
Autor:
Jie Li, Shuya Hu, Yate Ching Yuan, Yaguang Weng, Hongzhi Li, Keqiang Zhang, Shikha Gaur, Lixin Yang, Yun Yen, Xiwei Wu
Publikováno v:
Human Mutation. 35:575-584
Mutation of the tumor suppressor TP53 gene occurs in greater than half of all human cancers. In addition to loss of tumor suppressor function of wild-type TP53, gain-of-function mutations endow cancer cells with more malignant properties. R273 is a m
Autor:
Reiki Nishimura, Makoto Kubo, Charles Warden, Masato Takahashi, Karineh Petrossian, Noriko Kanaya, Zheng Liu, Yate Ching Yuan, Jingjing Ye, Shiuan Chen, Peiguo Chu, Tomofumi Osako, Masayuki Okido, Kazuo Shimada
Publikováno v:
Breast Cancer Research and Treatment. 137:93-107
Aromatase inhibitors (AIs) are important drugs for treating postmenopausal patients with hormone receptor (HR)-positive breast cancer. However, acquired resistance to AI therapies is a significant problem. Our study has revealed that the histone deac
Publikováno v:
Biochemical Pharmacology. 75:1161-1169
Aromatase cytochrome P450 (CYP19) converts androgen to estrogen. In this study, the interactions of four classes of compounds, 17beta-estradiol (the product of aromatase), 17-methyltestosterone (a synthetic androgen), dibenzylfluorescein (a synthetic
Autor:
Robert J. Hickey, George Somlo, Arthur D. Riggs, David Berz, Yate-Ching Yuan, Sailee Yadav, Kimlin Tam Ashing, Sushma Yadav
Publikováno v:
Cancer Research. 76:2160-2160
Triple negative breast cancer (TNBC) defined primarily by lack of expression of estrogen and progesterone hormone receptors (HR) and lacking HER2 overexpression and/or gene amplification (HER2) is an aggressive subtype with poor prognosis. Presentati
Human p53R2 (hp53R2) is a 351 residue p53-inducible ribonucleotide reductase (RNR) small subunit. It shares >80% sequence identity with hRRM2, the small RNR subunit responsible for normal maintenance of the deoxyribonucleotide (dNTP) pool used for DN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec6675ae706697e8f32bcddc8887745e
https://europepmc.org/articles/PMC2844085/
https://europepmc.org/articles/PMC2844085/
Autor:
Richard Jove, Ralf Buettner, Yate-Ching Yuan, Jianping Lin, Nagarajan Vaidehi, David Horne, M.L. Richard Yip
Publikováno v:
Journal of molecular graphicsmodelling. 28(4)
All signal transducers and activators of transcription (STAT) factors are a family of cytoplasmic transcription factors that mediate the signal response to cytokines, growth factors, and hormonal factors. The phosphorylation and subsequent activation
Autor:
Michael J. S. Dewar, Yate Ching Yuan
Publikováno v:
Journal of the American Chemical Society. 112:2088-2094
Etude theorique de la reaction E2 entre le methanolate et des ethanes monosubstitues CH 3 CH 2 X (X=Cl,Br,I,NO 2 ,OCOCF 3 ), et entre l'ammoniac des ions «oniums»: CH 3 CH 2 X + (X + =OH 2 + ,OH(CH 3 ) + ,O(CH 3 ) 2 + ,SH 2 + ,SH(CH 3 ) + ,NH 3 + )
Clinical trials have demonstrated the importance of aromatase inhibitor (AI) therapy in the effective treatment of hormone-dependent breast cancers. In contrast to tamoxifen, an antagonist of the estrogen receptor (ER), AIs have shown to be better to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393296dd4ec0abd39a18db1a1c1b4449
https://europepmc.org/articles/PMC2743954/
https://europepmc.org/articles/PMC2743954/
Publikováno v:
Molecular endocrinology (Baltimore, Md.). 21(2)
Aromatase converts androgens to aromatic estrogens. Aromatase inhibitors have been used as first-line drugs in the treatment of hormone-dependent breast cancer. Structural basis of the aromatization reaction and drug recognition by aromatase has rema
Publikováno v:
The Journal of steroid biochemistry and molecular biology. 102(1-5)
Clinical trials have demonstrated the importance of aromatase inhibitor (AI) therapy in the effective treatment of hormone-dependent breast cancers. Yet, as with all prolonged drug therapy, resistance to aromatase inhibitors does develop. To date, th